View Cancer Clinical Trials

Cancer Answer Line: 866.223.8100

Cancer Answer Line:

866.223.8100

View Cancer Clinical Trials

CASE 1811   |   CC00032
Utility of Early Versus Late Androgen Deprivation in Prostate Cancer Patients with Biochemical Relapse
Disease(s)
Prostate
Hospital(s)
Main Campus
Phase(s)
N/A
Stage(s)
N/A
Type(s)
Observational
Drug(s)
Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday

Description
  1. To measure the utility of treatment versus observation in patients with rising PSA
Inclusion Criteria
  1. All patients with rising PSA after definitive treatment of their prostate cancer with no evidence of metastatic disease are eligible for this study.
  2. The patient population includes patients with biochemical failure who are being followed at Taussig Cancer Institute or at Glickman clinics.
  3. The patient will be informed that their choice of whether to participate or not will have no influence on their medical care.
Exclusion Criteria
Exclusion Criteria Not Available

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2013 Cleveland Clinic. All rights reserved.